688399 硕世生物
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额(4,821)30,341145,925(113,144)1,964,878
投资活动产生之现金流量净额(303,504)(193,286)(873,013)462,348(717,888)
筹资活动产生之现金流量净额172,229(162,107)(94,756)55,259(667,426)
汇率变动对现金及现金等价物的影响(2,101)(1,443)850(1,266)757
现金及现金等价物净增加/(减少)(138,197)(326,495)(820,994)403,197580,322
期初现金及现金等价物余额483,513810,0081,631,0021,227,805647,483
期末现金及现金等价物余额345,316483,513810,0081,631,0021,227,805